Mounjaro and Low BMI: Does Your BMI Actually Rule You Out?

The decision you're probably trying to make

You've looked up your BMI, seen it land somewhere between 25 and 29, and you're wondering whether there's any realistic path to treatment. This is a question our prescribers hear most weeks, and the honest answer is: it depends on more than the number itself.

Mounjaro's UK licence draws the threshold at BMI 30 without any additional condition, or BMI 27 if you have at least one qualifying comorbidity. Below 27, the medicine is outside its licensed indication for weight management, and a responsible prescriber won't approve it on that basis. Between 27 and 29.9, the decision turns on your health profile, what conditions are present, how well they're managed, and whether treatment is clinically appropriate for you specifically.

The NHS patient information for tirzepatide sets out clearly that this is a medicine requiring clinical assessment, not a product that can be self-selected. That framing matters here: the threshold isn't a bureaucratic hurdle, it reflects where the clinical evidence supports use. You can read more about how eligibility criteria translate into a real consultation on our BMI for Mounjaro page.

What counts as a qualifying condition at lower BMI?

The conditions most commonly considered alongside a BMI of 27 to 29.9 are the same ones that appear in Mounjaro's licensed indication: type 2 diabetes, high blood pressure, dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea, and established cardiovascular disease. Prediabetes and polycystic ovary syndrome are also discussed in clinical practice, though the licence's primary list is the benchmark a prescriber works from.

What matters is not just whether a condition appears on your records, but whether it's genuinely weight-related and whether managing your weight is part of its treatment. A prescriber will want to understand your clinical context, not simply confirm a diagnostic code exists. If you're uncertain where your BMI sits relative to the qualifying threshold, the NHS BMI calculator is a straightforward place to check before you apply.

Ethnic background can shift the calculation. NICE guidance (confirmed in the tirzepatide appraisal TA1026) applies thresholds that are 2.5 kg/m² lower for several groups, meaning the qualifying BMI for those backgrounds is 24.5 with a comorbidity rather than 27. Our Mounjaro BMI 27 page covers this specific threshold in detail, and the lowest BMI for Mounjaro page explains where the floor sits.

Below 27: the clearer answer

If your BMI is below 27, Mounjaro is not within its licensed indication for weight management in the UK, and a prescriber working within appropriate clinical standards will not approve it for that purpose. This isn't about the number being arbitrary, the clinical trial programme that underpins the licence enrolled adults at BMI 30 and above (with lower-threshold criteria for comorbidities), so the evidence base doesn't extend to lower starting weights in the same way.

That distinction matters for your safety as much as for regulatory compliance. Prescribing outside a medicine's licensed indication without a compelling documented clinical reason is not something a GPhC-registered Independent Prescriber at a regulated pharmacy should do routinely. If you're close to the threshold, the right step is a proper assessment rather than a borderline guess.

For context on what the evidence shows at the licensed range (including how tirzepatide performs across the weight spectrum) our broader Mounjaro overview covers the clinical picture, and you can explore weight-loss treatment options more broadly if you'd like to understand what alternatives may be suitable at lower BMI values.

Cost, context, and what comes next

One thing worth knowing before you make any decision: private Mounjaro treatment is not inexpensive, and the cost doesn't change based on your BMI. It's worth reading our Mounjaro prices page to understand what a legitimate private prescription includes (consultation, prescriber review, and dispensing) so you're comparing like for like when you look at different providers.

Some people at a lower BMI turn to supplements or herbal products while they consider their options. If that's on your mind, our page on milk thistle and Mounjaro addresses one common question about over-the-counter supplements and GLP-1 treatment.

If you're in the qualifying range and want a proper clinical assessment, the right next step is a consultation with a GPhC-registered prescriber who will review your BMI, your health history, and any conditions that may be relevant. There's no obligation, and the picture becomes clearer once a real clinical review has taken place. You can find out more about our team and how that review works on the clinical team page. When you're ready, check your eligibility and start your free consultation.